Kaneka Corporation (TYO:4118)
Japan
· Delayed Price · Currency is JPY | Market Cap | 290.24B |
| Revenue (ttm) | 802.43B |
| Net Income (ttm) | 26.01B |
| Shares Out | 60.53M |
| EPS (ttm) | 415.83 |
| PE Ratio | 11.53 |
| Forward PE | 10.54 |
| Dividend | 160.00 (3.23%) |
| Ex-Dividend Date | Mar 30, 2026 |
| Volume | 348,900 |
| Average Volume | 279,160 |
| Open | 4,750.00 |
| Previous Close | 4,960.00 |
| Day's Range | 4,728.00 - 4,827.00 |
| 52-Week Range | 3,146.00 - 5,286.00 |
| Beta | 0.23 |
| RSI | 41.68 |
| Earnings Date | Feb 10, 2026 |
About Kaneka
Kaneka Corporation engages in the manufacture and sale of polyvinyl chloride (PVC), crosslinked PVC, PVC-PVAc polymers, paste PVC, acryl grafted-vinyl chloride copolymer, and chlorinated PVC in Japan and internationally. It provides impact modifiers, processing aids, specialty additives, toughener for thermosetting resins, silyl-terminated polyether, acrylic silicon, terminally reactive liquid acrylic, and biodegradable polymer, as well as engineering resin for injection molding, acrylic film, and isobutylene-based thermoplastic elastomer produ... [Read more]
Financial Performance
In fiscal year 2025, Kaneka's revenue was 807.20 billion, an increase of 5.89% compared to the previous year's 762.30 billion. Earnings were 25.31 billion, an increase of 9.00%.
Financial StatementsNews
Kaneka Medical America LLC Announces U.S. Launch of WaveSelect 1014 Guidewire
NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Kaneka Medical America LLC , a subsidiary company of Kaneka Corporation , innovating embolization coil technology for neurovascular therapies, today announc...